Ben Leach

Articles

Sorafenib Improves PFS in Thyroid Cancer

January 3rd 2013

A phase III trial of sorafenib in patients with locally advanced or metastatic RAI-refractory differentiated thyroid cancer met its primary endpoint of a statistically significant improvement in PFS.

Emerging Agents in Multiple Myeloma: An Overview

January 2nd 2013

More potent versions of existing therapies are currently under development and showing considerable promise in early clinical trials for patients with multiple myeloma.

Local Ablative Therapy Might Extend TKI Benefit in NSCLC

December 24th 2012

Local ablative therapy plus continuation on the same tyrosine kinase inhibitor could be utilized as a treatment alternative in metastatic non-small cell lung cancer.

Emerging Agents for the Treatment of Ovarian Cancer

December 22nd 2012

Although the association between VEGF and ovarian cancer has been known for quite some time, researchers are still struggling to use drugs that inhibit VEGF and angiogenesis in patients with the disease.

Novel Cancer Vaccine Fails To Significantly Improve Overall Survival in Lung Cancer

December 21st 2012

Results of a large phase III trial testing the efficacy of the investigational vaccine L-BLP25 in patients with advanced lung cancer found that the vaccine failed to show a statistically significant improvement in overall survival

Controlling Progression in Patients With Metastatic Colorectal Cancer

December 21st 2012

The prognosis for patients with colorectal cancer has benefited greatly from the advent of advances in chemotherapy and new agents, with nearly threefourths of stage I patients surviving for at least 5 years after diagnosis.

Study Results May Change Treatment Standard for Patients Receiving Transplants From Unrelated Donors

December 21st 2012

Patients receiving transplants from unrelated donors to treat various hematologic malignancies may benefit more from receiving adult stem cells harvested from bone marrow rather than peripheral-blood stem cells (the current standard).

Sexual Health Considerations in Cancer Treatment and Survivorship

December 20th 2012

Cancer impacts the lives of patients in many different ways, but one way in which adults facing a cancer diagnosis may be affected is the impact that the disease and its subsequent treatment can have on sexual function.

Adjuvant Bevacizumab Falls Short in Triple-Negative Breast Cancer

December 7th 2012

Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.

Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer

December 6th 2012

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

December 5th 2012

Postmenopausal women with advanced estrogen receptorâ€“positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Sentinel Lymph Node Surgery After Chemotherapy Shows Accuracy in Nodal Staging in Breast Cancer

December 5th 2012

Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.

New Data on Horizon in Several Key Areas

December 3rd 2012

Although new therapies have revolutionized the management of certain hematologic malignancies during the past 15 years, clinical trials currently under way hold the potential to yield new targeted agents and better treatment strategies.

In CML, Next-Generation TKIs Aim to Boost Outcomes

November 30th 2012

Researchers are continuing to investigate TKIs to help manage patients with CML who either do not respond to initial therapy or relapse after subsequent treatment.

FDA Approves Cabozantinib for Medullary Thyroid Cancer

November 29th 2012

The FDA approved cabozantinib, a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer.

Nab-Paclitaxel Extends PFS Versus Standard Chemotherapy in Patients With Metastatic Melanoma

November 26th 2012

A phase III trial that compared nab-paclitaxel (nab-P; Abraxane) with dacarbazine (DTIC) in patients with metastatic malignant melanoma (MMM) found that nab-P nearly doubled the median time to progression-free survival (PFS).

Biomarker May Predict Response to Bevacizumab in mCRC

November 26th 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer (mCRC) treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug, whereas others who do not express the biomarker could be spared from receiving unnecessary therapy.

FDA Grants Orphan Drug Status to Amatuximab for Malignant Pleural Mesothelioma

November 12th 2012

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.

Recently Approved Therapies Bring New Understanding in Management of Prostate Cancer

November 2nd 2012

After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.

Meeting Addresses Challenges Facing Urology Groups in Cancer Care

November 1st 2012

The 2012 LUGPA Annual Meeting is expected to gather more than 100 urology groups to discuss administrative, technological, regulatory, and medical challenges facing practices.